UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 54

Sortiert nach

Prospective Multicenter Study of the Impact of the 21-Gene Recurrence Score Assay on Medical Oncologist and Patient Adjuvant Breast Cancer Treatment Selection

Journal of clinical oncology, 2010-04, Vol.28 (10), p.1671-1676

2010

Volltextzugriff (PDF)

Phase III Randomized Intergroup Trial of Subtotal Lymphoid Irradiation Versus Doxorubicin, Vinblastine, and Subtotal Lymphoid Irradiation for Stage IA to IIA Hodgkin’s Disease

Journal of clinical oncology, 2001-11, Vol.19 (22), p.4238-4244

2001

Volltextzugriff (PDF)

Concurrent chemotherapy is associated with improved survival in elderly patients with bladder cancer undergoing radiotherapy

Cancer, 2017-09, Vol.123 (18), p.3524-3531

2017

Volltextzugriff (PDF)

Health Status and Quality of Life in Patients With Early-Stage Hodgkin’s Disease Treated on Southwest Oncology Group Study 9133

Journal of clinical oncology, 2003-09, Vol.21 (18), p.3512-3519

2003

Volltextzugriff (PDF)

Dose-Intense Chemotherapy Every 2 Weeks With Dose-Intense Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone May Improve Survival in Intermediate- and High-Grade Lymphoma: A Phase II Study of the Southwest Oncology Group (SWOG 9349)

Journal of clinical oncology, 2003-07, Vol.21 (13), p.2466-2473

2003

Volltextzugriff (PDF)

A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911

Blood, 2003-09, Vol.102 (5), p.1606-1612

2003

Volltextzugriff (PDF)

Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin’s disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208

Journal of cancer survivorship, 2017-02, Vol.11 (1), p.32-40

2017

Volltextzugriff (PDF)

Comparison of a Standard Regimen (CHOP) with Three Intensive Chemotherapy Regimens for Advanced Non-Hodgkin's Lymphoma

The New England journal of medicine, 1993-04, Vol.328 (14), p.1002-1006

1993

Volltextzugriff (PDF)

Interferon Alfa Consolidation After Intensive Chemotherapy Does Not Prolong the Progression-Free Survival of Patients With Low-Grade Non-Hodgkin’s Lymphoma: Results of the Southwest Oncology Group Randomized Phase III Study 8809

Journal of clinical oncology, 2000-05, Vol.18 (10), p.2010-2016

2000

Volltextzugriff (PDF)

Trends in utilization of novel oral therapeutic agents for men with metastatic castrate-resistant prostate cancer within the United States Veteran’s Affairs Health System

Journal of clinical oncology, 2016-01, Vol.34 (2_suppl), p.220-220

2016

Volltextzugriff (PDF)

Effect of concurrent chemotherapy on overall survival in elderly bladder cancer patients undergoing radiotherapy: A population-based analysis

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.e16000-e16000

2016

Volltextzugriff (PDF)

Association of treatment facility case volume with survival in patients undergoing radiotherapy/chemoradiotherapy for muscle-invasive bladder cancer: An analysis of the National Cancer Database

Journal of clinical oncology, 2017-02, Vol.35 (6_suppl), p.295-295

2017

Volltextzugriff (PDF)

Abstract P6-08-42: Association of metabolic syndrome, its components and multigene assays for recurrence risk

Cancer research (Chicago, Ill.), 2015-05, Vol.75 (9_Supplement), p.P6-P6-08-42

2015

Volltextzugriff (PDF)

Daily Subcutaneous Ultra-Low-Dose Interleukin 2 with Daily Low-Dose Interferon-α in Patients with Advanced Renal Cell Carcinoma

Clinical cancer research, 1999-09, Vol.5 (9), p.2374-2380

1999

Volltextzugriff (PDF)

Octreotide for Refractory Diarrhea Associated with Capecitabine

The Journal of pharmacy technology, 2004-07, Vol.20 (4), p.226-228

2004

Volltextzugriff (PDF)

Comparison of the intermediate risk 21-gene recurrence score (RS) with the 70-gene signature (GS) as a continuous variable, Magee equations, and Adjuvant! Online (AOL)

Journal of clinical oncology, 2014-09, Vol.32 (26_suppl), p.47-47

2014

Volltextzugriff (PDF)

A phase II pilot study of high-dose 24-hour continuous infusion of 5-FU and leucovorin and low-dose PALA for patients with colorectal cancer: a Southwest Oncology Group study

Investigational new drugs, 2004-11, Vol.22 (4), p.467-473

2004

Volltextzugriff (PDF)

Abstract S4-03: Identification of a notch-driven breast cancer stem cell gene signature for anti-notch therapy in an ER+ presurgical window model

Cancer research (Chicago, Ill.), 2015-05, Vol.75 (9_Supplement), p.S4-S4-03

2015

Volltextzugriff (PDF)

Phase II trials of high-dose interleukin-2 and lymphokine-activated killer cells in advanced breast carcinoma and carcinoma of the lung, ovary, and pancreas and other tumors

Journal of immunotherapy with emphasis on tumor immunology, 1994-10, Vol.16 (3), p.216

1994

Volltextzugriff (PDF)

Chemotherapy and combined modality treatment in Hodgkinʼs disease

Current opinion in oncology, 1991-10, Vol.3 (5), p.822-829

1991

Volltextzugriff (PDF)

Non-Hodgkin's lymphoma: management strategies

The New England journal of medicine, 1984-12, Vol.311 (23), p.1506

1984

Volltextzugriff (PDF)

A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma

Journal of clinical oncology, 1992-02, Vol.10 (2), p.275-281

1992

Volltextzugriff (PDF)

The hemodynamic effects of treatment with interleukin-2 and lymphokine-activated killer cells

Annals of internal medicine, 1988-12, Vol.109 (12), p.953

1988

Volltextzugriff (PDF)

Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimen

Journal of clinical oncology, 1990-10, Vol.8 (10), p.1630-1636

1990

Volltextzugriff (PDF)

A phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma

Journal of clinical oncology, 1991-04, Vol.9 (4), p.641-648

1991

Volltextzugriff (PDF)

1 – 25 von 54

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(52)
Mit Volltextzugriff
(44)

Publikationsform

Artikel
(54)

Sprache

Englisch
(54)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Humans
(43)
Life Sciences & Biomedicine
(42)
Science & Technology
(42)
Female
(27)
Oncology
(26)
Biological And Medical Sciences
(25)
Male
(25)
Medical Sciences
(25)
Middle Aged
(25)
Adult
(22)
Aged
(20)
Antineoplastic Agents
(15)
Pharmacology. Drug Treatments
(15)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(14)
Treatment Outcome
(13)
Immunotherapy
(10)
Chemotherapy
(9)
Drug Evaluation
(9)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(8)
Interleukin-2 - Adverse Effects
(8)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Prospective Multicenter Study of the Impact of the 21-Gene Recurrence Score Assay on Medical Oncologist and Patient Adjuvant Breast Cancer Treatment Selection

Phase III Randomized Intergroup Trial of Subtotal Lymphoid Irradiation Versus Doxorubicin, Vinblastine, and Subtotal Lymphoid Irradiation for Stage IA to IIA Hodgkin’s Disease

Concurrent chemotherapy is associated with improved survival in elderly patients with bladder cancer undergoing radiotherapy

Health Status and Quality of Life in Patients With Early-Stage Hodgkin’s Disease Treated on Southwest Oncology Group Study 9133

Dose-Intense Chemotherapy Every 2 Weeks With Dose-Intense Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone May Improve Survival in Intermediate- and High-Grade Lymphoma: A Phase II Study of the Southwest Oncology Group (SWOG 9349)

A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911

Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin’s disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208

Comparison of a Standard Regimen (CHOP) with Three Intensive Chemotherapy Regimens for Advanced Non-Hodgkin's Lymphoma

Interferon Alfa Consolidation After Intensive Chemotherapy Does Not Prolong the Progression-Free Survival of Patients With Low-Grade Non-Hodgkin’s Lymphoma: Results of the Southwest Oncology Group Randomized Phase III Study 8809

Trends in utilization of novel oral therapeutic agents for men with metastatic castrate-resistant prostate cancer within the United States Veteran’s Affairs Health System

Effect of concurrent chemotherapy on overall survival in elderly bladder cancer patients undergoing radiotherapy: A population-based analysis

Association of treatment facility case volume with survival in patients undergoing radiotherapy/chemoradiotherapy for muscle-invasive bladder cancer: An analysis of the National Cancer Database

Abstract P6-08-42: Association of metabolic syndrome, its components and multigene assays for recurrence risk

Daily Subcutaneous Ultra-Low-Dose Interleukin 2 with Daily Low-Dose Interferon-α in Patients with Advanced Renal Cell Carcinoma

Octreotide for Refractory Diarrhea Associated with Capecitabine

Comparison of the intermediate risk 21-gene recurrence score (RS) with the 70-gene signature (GS) as a continuous variable, Magee equations, and Adjuvant! Online (AOL)

A phase II pilot study of high-dose 24-hour continuous infusion of 5-FU and leucovorin and low-dose PALA for patients with colorectal cancer: a Southwest Oncology Group study

Abstract S4-03: Identification of a notch-driven breast cancer stem cell gene signature for anti-notch therapy in an ER+ presurgical window model

Phase II trials of high-dose interleukin-2 and lymphokine-activated killer cells in advanced breast carcinoma and carcinoma of the lung, ovary, and pancreas and other tumors

Chemotherapy and combined modality treatment in Hodgkinʼs disease

Non-Hodgkin's lymphoma: management strategies

A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma

The hemodynamic effects of treatment with interleukin-2 and lymphokine-activated killer cells

Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimen

A phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma

Suchergebnisse filtern